JP2014525429A - Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 - Google Patents

Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 Download PDF

Info

Publication number
JP2014525429A
JP2014525429A JP2014527686A JP2014527686A JP2014525429A JP 2014525429 A JP2014525429 A JP 2014525429A JP 2014527686 A JP2014527686 A JP 2014527686A JP 2014527686 A JP2014527686 A JP 2014527686A JP 2014525429 A JP2014525429 A JP 2014525429A
Authority
JP
Japan
Prior art keywords
seq
antigen
tlr agonist
aureus
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525429A5 (enExample
Inventor
ファビオ バグノーリ，
バーバラ バウドナー，
シモーネ ブファーリ，
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2014525429A publication Critical patent/JP2014525429A/ja
Publication of JP2014525429A5 publication Critical patent/JP2014525429A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2014527686A 2011-09-01 2012-08-31 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 Pending JP2014525429A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US61/530,162 2011-09-01
US201261607999P 2012-03-07 2012-03-07
US61/607,999 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (2)

Publication Number Publication Date
JP2014525429A true JP2014525429A (ja) 2014-09-29
JP2014525429A5 JP2014525429A5 (enExample) 2015-10-01

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527686A Pending JP2014525429A (ja) 2011-09-01 2012-08-31 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物

Country Status (14)

Country Link
US (1) US20140363461A1 (enExample)
EP (1) EP2763695A1 (enExample)
JP (1) JP2014525429A (enExample)
KR (1) KR20140066212A (enExample)
CN (1) CN104093418A (enExample)
AU (1) AU2012300765A1 (enExample)
BR (1) BR112014004782A2 (enExample)
CA (1) CA2847204A1 (enExample)
IL (1) IL231104A0 (enExample)
IN (1) IN2014CN02152A (enExample)
MX (1) MX2014002363A (enExample)
RU (1) RU2014112343A (enExample)
SG (1) SG11201400210RA (enExample)
WO (1) WO2013030378A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2414384B2 (en) * 2009-04-03 2023-05-03 Momenta Pharmaceuticals, Inc. Control of copolymer compositions
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
CA2825770A1 (en) 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
BR112014004782A2 (pt) * 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
DK2822947T3 (en) * 2012-03-07 2016-09-19 Glaxosmithkline Biologicals Sa ARGINAL SALTS OF A TLR-7 AGONIST
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
JP2015532594A (ja) * 2012-08-31 2015-11-12 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
EP2890394B1 (en) * 2012-08-31 2019-05-01 GlaxoSmithKline Biologicals SA Stabilised proteins for immunising against staphylococcus aureus
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JP2013503884A (ja) * 2009-09-02 2013-02-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67769T1 (de) 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
CN1980692A (zh) 2003-07-24 2007-06-13 麦克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
MXPA06000854A (es) 2003-07-24 2006-03-30 Merck & Co Inc Polipeptidos para inducir una respuesta inmune protectora en contra de staphylococcus aureus.
WO2005079315A2 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
US20090053235A1 (en) 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
PT2038290E (pt) 2006-07-07 2013-12-10 Gilead Sciences Inc Moduladores de receptor do tipo toll 7
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
EP2125792B1 (en) 2007-02-19 2010-12-01 GlaxoSmithKline LLC Purine derivatives as immunomodulators
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2155743B1 (en) 2007-05-08 2012-08-29 AstraZeneca AB Imidazoquinolines with immuno-modulating properties
CA2707030A1 (en) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
UA105764C2 (uk) 2008-03-24 2014-06-25 4 Сц Аг Заміщені імідазохіноліни
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102481352A (zh) * 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
WO2011007004A1 (en) 2009-07-16 2011-01-20 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Treatment of infections
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
BR112014004782A2 (pt) * 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
CN104519910B (zh) * 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
JP2015509963A (ja) * 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
JP6345603B2 (ja) * 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP2890394B1 (en) * 2012-08-31 2019-05-01 GlaxoSmithKline Biologicals SA Stabilised proteins for immunising against staphylococcus aureus
JP2015532594A (ja) * 2012-08-31 2015-11-12 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
CN104582723A (zh) * 2012-08-31 2015-04-29 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
EP2892553A1 (en) * 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
TR201807340T4 (tr) * 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
AU2015238512B2 (en) * 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JP2013503884A (ja) * 2009-09-02 2013-02-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着

Also Published As

Publication number Publication date
SG11201400210RA (en) 2014-03-28
CN104093418A (zh) 2014-10-08
IL231104A0 (en) 2014-04-30
IN2014CN02152A (enExample) 2015-09-04
RU2014112343A (ru) 2015-10-10
WO2013030378A1 (en) 2013-03-07
KR20140066212A (ko) 2014-05-30
CA2847204A1 (en) 2013-03-07
AU2012300765A1 (en) 2014-03-13
BR112014004782A2 (pt) 2017-03-21
MX2014002363A (es) 2014-04-14
US20140363461A1 (en) 2014-12-11
EP2763695A1 (en) 2014-08-13

Similar Documents

Publication Publication Date Title
US20140363461A1 (en) Adjuvanted formulations of staphylococcus aureus antigens
JP7295895B2 (ja) 追加免疫ワクチンのアジュバント化された処方物
CA3066792C (en) Neisseria meningitidis compositions and methods thereof
JP2010500399A (ja) 尿路病原性大腸菌由来の免疫原
JP2012152228A (ja) 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸
KR102027429B1 (ko) 돌연변이 스태필로코쿠스 항원
US20150258190A1 (en) Nicotinamide as adjuvant
JP2015529212A (ja) 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
JP2012528805A (ja) オクロバクトラム・インターメディウムのリポ多糖類および哺乳動物の免疫刺激剤としてのそれらの使用
JP2015509520A (ja) 狂犬病ウイルス免疫原のアジュバント化製剤
CN100384476C (zh) 含有作为疫苗辅药的磷酸铁的疫苗组合物
JP2015532594A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
KR20240147612A (ko) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
NZ747917B2 (en) Neisseria meningitidis compositions and methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170206